All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| CYCC / Bio Green Med Solution, Inc.
|
|
|
|
|
|
|
|
| SURF / Surface Oncology Inc
|
|
|
|
|
|
|
|
| IVA / Inventiva S.A. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| MREO / Mereo BioPharma Group plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| CLDX / Celldex Therapeutics, Inc.
|
|
|
|
|
|
|
|
| BLSA / BCLS Acquisition Corp - Class A
|
|
|
|
|
|
|
|
| KALV / KalVista Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| VTGN / Vistagen Therapeutics, Inc.
|
|
|
|
|
|
|
|
| DYNE / Dyntek Inc
|
|
|
|
|
|
|
|
| CBAY / CymaBay Therapeutics, Inc.
|
|
|
|
|
|
|
|
| 859319303 / Sterling Financial Corp
|
|
|
|
|
|
|
|
| US33830X1046 / Five Prime Therapeutics Inc
|
|
|
|
|
|
|
|
| EPIX / ESSA Pharma Inc.
|
|
|
|
|
|
|
|
| CCCC / C4 Therapeutics, Inc.
|
|
|
|
|
|
|
|
| PMVP / PMV Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| KRON / Kronos Bio, Inc.
|
|
|
|
|
|
|
|
| VRDN / Viridian Therapeutics, Inc.
|
|
|
|
|
|
|
|
| MRSN / Mersana Therapeutics, Inc.
|
|
|
|
|
|
|
|
| LSAQ / LifeSci Acquisition II Corp
|
|
|
|
|
|
|
|
| RLMD / Relmada Therapeutics, Inc.
|
|
|
|
|
|
|
|
| GNCA / Genocea Biosciences Inc
|
|
|
|
|
|
|
|
| MGNX / MacroGenics, Inc.
|
|
|
|
|
|
|
|
| PTGX / Protagonist Therapeutics, Inc.
|
|
|
|
|
|
|
|
| US2103731061 / Constellation Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| MCRB / Seres Therapeutics, Inc.
|
|
|
|
|
|
|
|
| KURA / Kura Oncology, Inc.
|
|
|
|
|
|
|
|
| ACRS / Aclaris Therapeutics, Inc.
|
|
|
|
|
|
|
|
| SBTX / Silverback Therapeutics Inc
|
|
|
|
|
|
|
|
| ISEE / IVERIC bio Inc
|
|
|
|
|
|
|
|
| TPST / Tempest Therapeutics, Inc.
|
|
|
|
|
|
|
|
| TRIL / Trillium Therapeutics Inc
|
|
|
|
|
|
|
|
| IMVT / Immunovant, Inc.
|
|
|
|
|
|
|
|
| SNDX / Syndax Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| COGT / Cogent Biosciences, Inc.
|
|
|
|
|
|
|
|
| XENE / Xenon Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
